Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1996-10-24
|
pubmed:abstractText |
Fluconazole (800-1,000 mg i.v.) was administered to 14 consecutive patients with AIDS and cryptococcal meningitis. At 10 weeks the rate of clinical success was 54.5% (six of 11 patients responded to fluconazole); the Kaplan-Meier estimate of the response rate was 67.1%, and the overall mortality rate was 18.2% (two of 11 patients died). At the end of treatment, eight (72.7%) of 11 patients responded to fluconazole. The median time to the first negative cerebrospinal fluid (CSF) culture was 33.5 days (95% confidence interval, 18.3-67.3); the median time for patients with initial CSF cryptococcal antigen titers of > or = 1:1,024 was 66 days compared with 18 days for patients with initial CSF cryptococcal antigen titers of < 1:1,024 (P = .06). The median time to the first negative CSF culture for patients with an isolate for which the minimum inhibitory concentration (MIC) was 4 micrograms/mL was 56 days compared with 16 days for patients with an isolate for which the MIC was < 4 micrograms/mL (P = .11). The mean serum and CSF levels of fluconazole at steady state were 42.47 +/- 26.31 micrograms/mL and 36.63 +/- 21.08 micrograms/mL, respectively (ratio of CSF:serum, 0.86). No treatment was interrupted and no dose was tapered because of side effects. High-dose fluconazole might be an effective and well-tolerated therapeutic option for patients with AIDS and acute cryptococcal meningitis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1058-4838
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
838-40
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8722942-AIDS-Related Opportunistic Infections,
pubmed-meshheading:8722942-Adult,
pubmed-meshheading:8722942-Aged,
pubmed-meshheading:8722942-Antifungal Agents,
pubmed-meshheading:8722942-Antigens, Fungal,
pubmed-meshheading:8722942-Cryptococcus,
pubmed-meshheading:8722942-Drug Tolerance,
pubmed-meshheading:8722942-Female,
pubmed-meshheading:8722942-Fluconazole,
pubmed-meshheading:8722942-Humans,
pubmed-meshheading:8722942-Male,
pubmed-meshheading:8722942-Meningitis, Cryptococcal,
pubmed-meshheading:8722942-Middle Aged,
pubmed-meshheading:8722942-Time Factors
|
pubmed:year |
1996
|
pubmed:articleTitle |
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
|
pubmed:affiliation |
Institute of Infectious Diseases, University of Perugia, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|